Yoshitomi Pharmaceutical Industries, Ltd.

Hiroshi Yasuda

Takanori Oe

Tsutomu Yamanaka

Mineo Tsuruda

Kazuyuki Kawasaki

Hiroshi Mikashima

Michio Nakanishi

Kazuhiro Goto

Mitsuharu Sano

Toshihiro Kobayakawa

Kunio Osuga

.alpha.-(2,6-dimethyl-4-carboxyphenyl)-2-methyl-5-(1-imidazolyl)-benzenemet hanol, pharmaceutically acceptable metal salts forms thereof, acid addition salt forms thereof, amino acid addition salt forms thereof, hydrate forms thereof and mixtures thereof. Such compounds have inhibitory activities on biosynthesis of thromboxane A.sub.2, inhibitory activities on platelet aggregation, vasodilative activities and protective effects against liver disorders.

Imidazole derivatives

2(4-n-Hexadecyl amino or oxy phenyl) 5 ethoxy oxazoleacetic acid

Oxazole- and thiazole-alkanoic acid compounds useful as drugs for the treatment of atherosclerosis with lipid metabolism disorder, and having the formula: ##STR1## wherein R is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an aralkyl group, a pyridylmethyl group or a tocopheryl group; each of R.sup.1 and R.sup.2 is a hydrogen atom or a halogen atom; R.sup.3 is a hydrogen atom, a halogen atom or an alkyl group having 1 to 4 carbon atoms; R.sup.4 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms or a trifuloromethyl group; each of X and Y is an oxygen atom or a sulfur atom; and A is a straight or branched alkylene group having 1 to 4 carbon atoms, and pharmaceutically acceptable salts thereof are disclosed.

Oxazole- and thiazole-alkanoic acid compounds

Pharmaceutical compositions containing 2-amino-6-benzyl-3-ethoxycarbonyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine hydrochloride and a method of using such compositions in treatment of liver dysfunction in mammals are disclosed.

Treatment of liver dysfunction with

Growing community of inventors

Nakatsu, Japan

Hiroshi Yasuda